Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04170543 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Diabetic Kidney Disease Study
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 609
- Enrollment target
NCT04170543 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 609 participants.
The verdict
NCT04170543, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 609 participants
- Enrollment target
Study Summary
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG MEDI3506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04170543
The ClinicalTrials.gov registry entry for NCT04170543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04170543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04170543 about?
NCT04170543 is a clinical study titled "A Phase 2b Diabetic Kidney Disease Study". A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
What is the current status of trial NCT04170543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 609 participants. The study started on 2019-11-18. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04170543?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), MEDI3506 (DRUG).
Who is sponsoring clinical trial NCT04170543?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.